Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection

Gregory J. Dore, Eric Lawitz, Christophe Hézode, Stephen D. Shafran, Alnoor Ramji, Harvey A. Tatum, Gloria Taliani, Albert Tran, Maurizia R. Brunetto, Serena Zaltron, Simone I. Strasser, Nina Weis, Wayne Ghesquiere, Samuel S. Lee, Dominique Larrey, Stanislas Pol, Hugh Harley, Jacob George, Scott K. Fung, Victor De LédinghenPeggy Hagens, Fiona McPhee, Dennis Hernandez, David Cohen, Elizabeth Cooney, Stephanie Noviello, Eric A. Hughes

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint Dive into the research topics of 'Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection'. Together they form a unique fingerprint.

Medicine & Life Sciences